Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mindray Doubles Patient Monitor Biz, Builds U.S. Presence With Acquisition

This article was originally published in The Gray Sheet

Executive Summary

China-based Mindray Medical will supply components for Datascope's patient monitoring business unit after acquiring the subsidiary for $202 million in a deal announced March 11

You may also be interested in...



China’s Mindray Refutes Merit Of Report That Sent Stock Plummeting

Mindray stock recovers from freefall after allegations that China’s leading medical device company overstated its earnings and engaged in fraudulent accounting practices.

People In Brief

Roche changing of guard: Roche Molecular Diagnostics CEO Daniel O'Day will head the Swiss firm's entire test business at year-end when current diagnostics CEO Juergen Schwiezer retires, Roche said Sept. 8. O'Day's new title will be chief operating officer, rather than CEO, of the Diagnostics Division, but like Schwiezer he will report directly to Roche CEO Severin Schwan. Under the new structure, the head of the diabetes care division, Burkhard Piper, will report to O'Day, rather than to Schwan, as Piper has been doing since 2008 when Schwan took over the company. Schwiezer took the helm of the diagnostics unit last year to replace Schwan, who previously ran the laboratory products business (1"The Gray Sheet" Oct. 8, 2007). Also as part of the changes, Pharma Division head William M. Burns will be replaced by Pascal Soriot, who has led Genentech since Roche acquired the biotech firm earlier this year

People In Brief

Roche changing of guard: Roche Molecular Diagnostics CEO Daniel O'Day will head the Swiss firm's entire test business at year-end when current diagnostics CEO Juergen Schwiezer retires, Roche said Sept. 8. O'Day's new title will be chief operating officer, rather than CEO, of the Diagnostics Division, but like Schwiezer he will report directly to Roche CEO Severin Schwan. Under the new structure, the head of the diabetes care division, Burkhard Piper, will report to O'Day, rather than to Schwan, as Piper has been doing since 2008 when Schwan took over the company. Schwiezer took the helm of the diagnostics unit last year to replace Schwan, who previously ran the laboratory products business (1"The Gray Sheet" Oct. 8, 2007). Also as part of the changes, Pharma Division head William M. Burns will be replaced by Pascal Soriot, who has led Genentech since Roche acquired the biotech firm earlier this year

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT025891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel